Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658970 | 0.83 | NFKBIA (0.47) | TP53HTTALDH1A1TSHRPOLB | |
| SCHEMBL3499438 | 0.80 | NPC1 (0.34) | ALDH1A1POLBPKMMAPTNPC1 | |
| SCHEMBL1653985 | 0.77 | ALDH1A1 (0.36) | HTTALDH1A1TSHRPOLBMAPT | |
| SCHEMBL1654045 | 0.76 | ALDH1A1 (0.33) | HTTALDH1A1PKMMAPTNPC1 | |
| SCHEMBL1653663 | 0.75 | NFKBIA (0.46) | TP53HTTALDH1A1TSHRPOLB | |
| SCHEMBL1653883 | 0.75 | TSHR (0.33) | ALDH1A1TSHRMAPTNPC1HPGD | |
| SCHEMBL15888918 | 0.73 | NFKBIA (0.42) | TP53HTTALDH1A1TSHRPOLB | |
| SCHEMBL1653252 | 0.72 | TAS2R14 (0.32) | — | |
| SCHEMBL1653797 | 0.71 | CCR2 (0.39) | HTTALDH1A1TSHRPKMMAPT | |
| SCHEMBL3499443 | 0.71 | TUBB4A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410087-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20100144702-A1 | INDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144702-A1 | INDOLE COMPOUND | GCKR, GPR119, SLC5A1 | CYP2D6 251/4885CYP2C9 658/4885CYP2C19 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.